NO20052714L - Fremgangsmater og materialer for behandling av inflammatoriske tilstander - Google Patents

Fremgangsmater og materialer for behandling av inflammatoriske tilstander

Info

Publication number
NO20052714L
NO20052714L NO20052714A NO20052714A NO20052714L NO 20052714 L NO20052714 L NO 20052714L NO 20052714 A NO20052714 A NO 20052714A NO 20052714 A NO20052714 A NO 20052714A NO 20052714 L NO20052714 L NO 20052714L
Authority
NO
Norway
Prior art keywords
methods
materials
inflammatory conditions
treating inflammatory
mammal
Prior art date
Application number
NO20052714A
Other languages
English (en)
Norwegian (no)
Other versions
NO20052714D0 (no
Inventor
Rikard Holmdahl
Lars T Hellmann
Original Assignee
Resistentia Pharmaceuticals Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Resistentia Pharmaceuticals Ab filed Critical Resistentia Pharmaceuticals Ab
Publication of NO20052714D0 publication Critical patent/NO20052714D0/no
Publication of NO20052714L publication Critical patent/NO20052714L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/806—Antigenic peptides or proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
NO20052714A 2002-12-02 2005-06-06 Fremgangsmater og materialer for behandling av inflammatoriske tilstander NO20052714L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43027802P 2002-12-02 2002-12-02
PCT/IB2003/006344 WO2004050111A2 (fr) 2002-12-02 2003-12-01 Techniques et materiaux de traitement d'etats inflammatoires

Publications (2)

Publication Number Publication Date
NO20052714D0 NO20052714D0 (no) 2005-06-06
NO20052714L true NO20052714L (no) 2005-08-10

Family

ID=32469435

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052714A NO20052714L (no) 2002-12-02 2005-06-06 Fremgangsmater og materialer for behandling av inflammatoriske tilstander

Country Status (15)

Country Link
US (2) US7361742B2 (fr)
EP (1) EP1569958B1 (fr)
JP (1) JP2006507834A (fr)
KR (1) KR20050090390A (fr)
CN (1) CN1745098A (fr)
AT (1) ATE423133T1 (fr)
AU (1) AU2003288472A1 (fr)
CA (1) CA2508302A1 (fr)
DE (1) DE60326264D1 (fr)
ES (1) ES2323692T3 (fr)
MX (1) MXPA05005909A (fr)
NO (1) NO20052714L (fr)
NZ (1) NZ540735A (fr)
RU (1) RU2344144C2 (fr)
WO (1) WO2004050111A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7462325B2 (en) * 2001-11-30 2008-12-09 Nomadics, Inc. Luminescent polymer particles
DE60326264D1 (de) * 2002-12-02 2009-04-02 Resistentia Pharmaceuticals Ab Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält
DK1853305T3 (en) * 2005-02-04 2014-12-01 Survac Aps Survivin-peptide vaccine
US7858363B2 (en) * 2006-07-22 2010-12-28 Zymo Research Corporation Plasmid DNA isolation
KR100973428B1 (ko) * 2008-05-19 2010-08-03 한국과학기술연구원 말토오스 결합 단백질을 이용한 생리활성 폴리펩타이드의고정화 방법
EP2468295A1 (fr) 2010-12-21 2012-06-27 Affiris AG Vaccins à base de peptides de la proteine C5a du complement
PT2817329T (pt) 2012-02-20 2019-04-01 Swedish Orphan Biovitrum Ab Publ Polipeptioos que se ligam ao complemento humano c5

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
NO162210C (no) * 1987-07-20 1989-11-22 Fasting Biotech As Monoklonale antistoffer mot c5a for in-vitro anvendelse ved immunologiske kvantitative teknikker eller ved isolering av c5a.
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP0832223A1 (fr) * 1995-06-05 1998-04-01 Novartis AG ANTAGONISTES DES RECEPTEURS DE C5a NE PRESENTANT SENSIBLEMENT AUCUNE ACTIVITE AGONISTE ET LEURS PROCEDES DE PREPARATION
CA2232344C (fr) * 1995-10-20 2005-04-05 University Of Nebraska Board Of Regents Composition et procedes permettant d'accentuer les reponses immunitaires dues aux cellules presentatrices d'antigene
US6673346B1 (en) 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
ES2483991T3 (es) 2000-10-10 2014-08-08 Genentech, Inc. Anticuerpos contra C5 que inhibe la activación de las células endoteliales de tipo II
DE60219801T3 (de) 2001-08-17 2016-06-16 Genentech, Inc. KOMPLEMENT-INHIBITOREN DIE AN C5 UND C5a BINDEN OHNE DIE BILDUNG VON C5b ZU HEMMEN
DE60326264D1 (de) * 2002-12-02 2009-04-02 Resistentia Pharmaceuticals Ab Verfahren und materialien zur behandlung von entzündungen unter verwendung eines polypeptides das einen eigenen-c5 aminosaüresegment und einen nicht-eigenen aminosaüresegment enthält

Also Published As

Publication number Publication date
EP1569958A2 (fr) 2005-09-07
WO2004050111A2 (fr) 2004-06-17
DE60326264D1 (de) 2009-04-02
AU2003288472A1 (en) 2004-06-23
MXPA05005909A (es) 2005-08-26
US7361742B2 (en) 2008-04-22
EP1569958B1 (fr) 2009-02-18
ATE423133T1 (de) 2009-03-15
RU2005120785A (ru) 2006-01-20
CN1745098A (zh) 2006-03-08
CA2508302A1 (fr) 2004-06-17
KR20050090390A (ko) 2005-09-13
JP2006507834A (ja) 2006-03-09
NO20052714D0 (no) 2005-06-06
US20040214768A1 (en) 2004-10-28
NZ540735A (en) 2008-08-29
WO2004050111A3 (fr) 2004-07-29
RU2344144C2 (ru) 2009-01-20
ES2323692T3 (es) 2009-07-23
US20080262197A1 (en) 2008-10-23

Similar Documents

Publication Publication Date Title
NO20052714L (no) Fremgangsmater og materialer for behandling av inflammatoriske tilstander
CY1124137T1 (el) Μεθοδος για την παραγωγη αντισωματων περιοχης
NO20082905L (no) Anti-IL-17 antistoff
CL2009002004A1 (es) Anticuerpo o fragmento del mismo que se une al receptor de interleuquina 4 que comprende una region variable de cadena liviana y pesada; secuencias de acido nucleico que codifica dichas regiones; vector que comprende dicha secuencia; celula huesped; metodo para producir dicho anticuerpo; y uso de dicho anticuerpo para trastornos inmunologicos.
EA201301072A1 (ru) Антитела против il-23p19 и их применение
CY1118443T1 (el) Anti-tnf αντισωματα, συνθεσεις, μεθοδοι και χρησεις
WO2004042017A3 (fr) Methodes et compositions pouvant augmenter la production d'anticorps
BRPI0606790A2 (pt) anticorpo humano isolado ou porção de ligação de antìgeno do mesmo, polipeptìdeo isolado, composição, ácido nucleico isolado, vetor de expressão célula hospedeira, vacina contra a raiva, kit, uso de um anticorpo monoclonal humano isolado ou porção de ligação de antìgeno do mesmo, ou de uma quantidade eficaz de uma composição, método para identificar um anticorpo ou um fragmento do mesmo, anticorpo ou fragmento do mesmo, anticorpo ou fragmento do mesmo,e, glicoproteìna.
NO20091283L (no) Humane antistoffer som binder CXCR4 og anvendelser derav
NO20065874L (no) Antistoffer og beslektede molekyler som bindes til PSCA proteiner
NO20061203L (no) Fremgangsmate og sammensetning for rekontormering av multiepitopiske antigener for a initiere en immunrespons
NO20083062L (no) Humane monoklonale antistoffer mot fukosyl-GM1 og fremgangsmater for anvendelse av anti-fukosyl-GM1
BR0311471A (pt) anticorpo anti-cd16a, e, métodos de redução de uma resposta imune deletéria em um mamìfero e de tratamento de uma resposta imune deletéria em um mamìfero
WO2006089230A3 (fr) Anticorps monoclonaux humains diriges contre l'antigene d'enveloppe specifique de la prostate
NO20076662L (no) Deteksjon av et malantigen uavhengig av tilstedevaerelse eller fravaer av et korresponderende terapeutisk antistoff
WO2007016340A3 (fr) Produits de ribosome défectueux dans les blebs (flux salivaires inconscients) et procédés d’utilisation pour stimuler une réponse immunitaire
WO2008076255A3 (fr) Lymphopoïétine stromale thymique (tslp) canine et utilisations associées
NO20055210L (no) Inhibitorproteiner av en protease og anvendelse derav
ATE428771T1 (de) Antikörper gegen hundepankreaslipase
WO2005074973A3 (fr) Methode permettant d'induire ou de moduler une reponse immunitaire
WO2007008708A3 (fr) Methodes destinees a predire des sites de glycosylation de hyp pour des proteines exprimees et secretees dans des cellules vegetales, et methodes et produits associes
NO20065651L (no) Spesifikke bindingsmedlemmer
JP2009544971A5 (fr)
WO2004067750A3 (fr) Proteines et genes de tc de xenorhabdus destines a la lutte antiparasitaire
WO2006034335A3 (fr) Procede de detection du cancer base sur la reaction immunitaire a boris

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application